Placement on two elite stock screens and promising technical indicators put Ligand Pharmaceuticals (LGND) in focus. Ligand stock has landed a spot on the latest list of new buys by the best mutual funds. The monthly screen showed savvy money managers scooped over $248 million worth of Ligand stock in their latest reporting period.
Further showcasing Wall Street's interest, the…
Extract — continue reading at the source.
Related stories
'Moneymaxxing' is the latest personal finance trend. Will it work for you?
CrowdStrike’s stock soars after AI fuels the cybersecurity company’s ‘best quarter’ ever
Nvidia sales more than double to $96bn on bumper AI demand
Salesforce’s stock surges as AI momentum fuels revenue growth
I just had my first baby and don’t want to go back to work. Is quitting for a year a bad idea?
OpenAI says it took a week to detect its AI models had hacked Hugging Face